
Bristol-Myers Squibb Company: updates and filings
Price
$59.24
November 20, 2026Market cap $121B
What Ploutos Investor adds for Bristol-Myers Squibb
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
July 2026
April 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 29, 2026Results of operations, Regulation FD disclosureForm8-K
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 30, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 30, 2026Results of operations, Regulation FD disclosureForm8-K
- Jun 5, 2026Employee stock plan reportfor the period to Dec 31, 2025Form11-K
- Jun 5, 2026Employee stock plan reportfor the period to Dec 31, 2025Form11-K
- Jun 5, 2026Employee stock plan reportfor the period to Dec 31, 2025Form11-K
- May 8, 2026Shares registered for employeesFormS-8
- May 8, 2026Shareholder voteForm8-K
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 30, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 17, 2026Additional annual meeting materialFormDEFA14A
- Mar 27, 2026FilingForm15-12G
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 25, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 25, 2026Additional annual meeting materialFormDEFA14A
- Mar 25, 2026Annual meeting proxy statementFormDEF 14A
- Feb 11, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Jan 12, 2026Regulation FD disclosureForm8-K
- Nov 18, 2025Other material eventsForm8-K
- Nov 12, 2025Exchange certification of a listingFormCERT
- Nov 10, 2025Securities listed on an exchangeForm8-A12B
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 29, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 30, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 30, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jun 5, 2026 | 11-K | Employee stock plan reportfor the period to Dec 31, 2025 | Document |
| Jun 5, 2026 | 11-K | Employee stock plan reportfor the period to Dec 31, 2025 | Document |
| Jun 5, 2026 | 11-K | Employee stock plan reportfor the period to Dec 31, 2025 | Document |
| May 8, 2026 | S-8 | Shares registered for employees | Document |
| May 8, 2026 | 8-K | Shareholder vote | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 30, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 17, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 27, 2026 | 15-12G | Filing | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 25, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 25, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 25, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Feb 11, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jan 12, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 18, 2025 | 8-K | Other material events | Document |
| Nov 12, 2025 | CERT | Exchange certification of a listing | Document |
| Nov 10, 2025 | 8-A12B | Securities listed on an exchange | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Mar 15, 1994: every report, 8-K, meeting and letter. Of its other filings (1,240 in all), the newest. Of its note and share prospectuses (424B, FWP), the newest 40 of 52.
The full analysis
What do Bristol-Myers Squibb's filings show?
The filings are where every one of Bristol-Myers Squibb's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.